Table 1.
Basic study and patient characteristics.
| Authors | Year | Country | Study Design | Type Of Patients Evaluated | PCa Patients Performing 18F-PSMA-1007 PET/CT | Mean/Median Age (Years) |
Gleason Score (Percentage) |
Median PSA Values Before PET/CT (ng/ml) (Range) |
|---|---|---|---|---|---|---|---|---|
| Anttinen et al. [24] | 2020 | Finland | Prospective single-center | Patients with high-risk PCa at staging | 80 | Mean: 70 ± 7 | GS 6: 3 (4%) GS 7: 30 (37%) GS 8: 13 (16%) GS 9–10: 34 (43%) |
12 (3–2000) |
| Giesel et al. [25] | 2017 | Germany | Retrospective single-center | Patients with high-risk PCa at staging | 10 | Median: 65 (55–77) | GS 7: 3 (30%) GS 8: 2 (20%) GS 9: 5 (50%) |
14 (5.8–87.3) |
| Giesel et al. [26] | 2018 | Germany and South Africa | Prospective bicentric | Patients with PCa at staging | 12 | Median: 66 (54–82) | GS 6: 1 (8%) GS 7: 5 (42%) GS 8: 4 (33%) GS 9: 2 (17%) |
85 (10–279.8) |
| Hong et al. [27] | 2020 | China | Retrospective single-center | Patients with non-metastatic intermediate- or high-risk PCa at staging | 101 | Median: 69 (43–87) | GS 6: 4 (4%) GS 7: 67 (66%) GS 8: 9 (9%) GS 9: 21 (21%) |
11.1 (0.97–178.2) |
| Kesch et al. [28] | 2017 | Germany | Retrospective single-center | Patients with high-risk PCa at local staging | 10 | Median: 67 (55–77) | GS 7: 3 (30%) GS 9: 7 (70%) |
13.1 (5.8–40) |
| Kuten et al. [29] | 2020 | Israel | Prospective single-center | Patients with intermediate- or high-risk PCa at staging | 16 | Median: 68 (56–74) | GS 6: 2 (12%) GS 7: 11 (69%) GS 8: 3 (19%) |
6.35 (3.5–14.44) |
| Privé et al. [30] | 2020 | Netherlands | Retrospective single-center | Patients with intermediate- or high-risk PCa at staging | 53 | Median: 67 | GS 6: 5 (9%) GS 7: 19 (36%) GS 8: 12 (23%) GS 9–10: 17 (32%) |
12 |
| Sprute et al. [31] | 2020 | Germany, Chile, Japan | Retrospective multicenter | Patients with PCa at staging | 87 | Median: 69 (48–78) | GS 6: 3% GS 7: 60% GS 8: 7% GS 9: 30% |
11.7 (0.1–120) |
Legend: CT = computed tomography; GS = Gleason score; PCa = prostate cancer; PET = positron emission tomography; PSA = prostate specific antigen; PSMA = prostate specific membrane antigen.